Wicki A - Search Results

1

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.

Xue G, Zippelius A, Wicki A, Mandalà M, Tang F, Massi D, Hemmings BA. Xue G, et al. Among authors: wicki a. J Natl Cancer Inst. 2015 Jun 11;107(7):djv171. doi: 10.1093/jnci/djv171. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 26071042 Review.

2

Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.

Pavic M, Wolfer A, Li Q, Gircys A, Juritz S, Wicki A, Cerny T, Rohr UP. Pavic M, et al. Among authors: wicki a. J Clin Oncol. 2023 Nov 10;41(32):4973-4975. doi: 10.1200/JCO.23.01442. Epub 2023 Sep 21. J Clin Oncol. 2023. PMID: 37733978 No abstract available.

3

The potential role of podoplanin in tumour invasion.

Wicki A, Christofori G. Wicki A, et al. Br J Cancer. 2007 Jan 15;96(1):1-5. doi: 10.1038/sj.bjc.6603518. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179989 Free PMC article. Review.

4

[Melanoma- finally good news].

Wicki A, Arnold AW, Itin PH, Zippelius A. Wicki A, et al. Praxis (Bern 1994). 2013 May 22;102(11):667-70. doi: 10.1024/1661-8157/a001293. Praxis (Bern 1994). 2013. PMID: 23692905 Review. German.

5

Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.

Conen K, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, Gross M, Zimmermann F, Zippelius A. Conen K, et al. Among authors: wicki a. Dermatology. 2015;230(1):1-4. doi: 10.1159/000365918. Epub 2014 Nov 29. Dermatology. 2015. PMID: 25472806 Review.

6

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.

Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD. Koelzer VH, et al. Among authors: wicki a. J Immunother Cancer. 2016 Mar 15;4:13. doi: 10.1186/s40425-016-0117-1. eCollection 2016. J Immunother Cancer. 2016. PMID: 26981243 Free PMC article.

7

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Wicki A, Mandalà M, Massi D, Taverna D, Tang H, Hemmings BA, Xue G. Wicki A, et al. Physiol Rev. 2016 Jul;96(3):805-29. doi: 10.1152/physrev.00024.2015. Physiol Rev. 2016. PMID: 27142452 Free article. Review.

8

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.

Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD. Koelzer VH, et al. Among authors: wicki a. J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016. J Immunother Cancer. 2016. PMID: 27532022 Free PMC article.

9

AKT-ions with a TWIST between EMT and MET.

Tang H, Massi D, Hemmings BA, Mandalà M, Hu Z, Wicki A, Xue G. Tang H, et al. Among authors: wicki a. Oncotarget. 2016 Sep 20;7(38):62767-62777. doi: 10.18632/oncotarget.11232. Oncotarget. 2016. PMID: 27623213 Free PMC article. Review.

10

Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?

Prêtre V, Wicki A. Prêtre V, et al. Among authors: wicki a. Semin Cancer Biol. 2018 Feb;48:70-77. doi: 10.1016/j.semcancer.2017.04.011. Epub 2017 May 1. Semin Cancer Biol. 2018. PMID: 28473255 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters